• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Neurological consequences of COVID-19
Pharmacol Rep. 2022 Sep 30. doi: 10.1007/s43440-022-00424-6. Online ahead of print.ABSTRACTIn December 2019, cases of pneumonia caused by infection with the previously unknown severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leading to coronavirus disease 2019 (COVID-19), were identified. Typical manifestations of COVID-19 are fever, cough, fatigue and dyspnoea. Initially, it was thought that the mechanism of action of SARS-CoV-2 was only associated with respiratory tract invasion, but it was later revealed that the infection might involve many other organs and systems, including the central and peripheral ner...
Source: Pharmacological Reports - September 30, 2022 Category: Drugs & Pharmacology Authors: Waldemar Brola Maciej Wilski Source Type: research

Role of the renin-angiotensin system in NETosis in the coronavirus disease 2019 (COVID-19)
Biomed Pharmacother. 2022 Feb 14;148:112718. doi: 10.1016/j.biopha.2022.112718. Online ahead of print.ABSTRACTMyocardial infarction and stroke are the leading causes of death in the world. Numerous evidence has confirmed that hypertension promotes thrombosis and induces myocardial infarction and stroke. Recent findings reveal that neutrophil extracellular traps (NETs) are involved in the induction of myocardial infarction and stroke. Meanwhile, patients with severe COVID-19 suffer from complications such as myocardial infarction and stroke with pathological signs of NETs. Due to the extremely low amount of virus detected i...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 17, 2022 Category: Drugs & Pharmacology Authors: Qingguang Zhang Shang Ling Kaili Hu Jun Liu Jin-Wen Xu Source Type: research

Adverse Cardiovascular Effects of Anti-COVID-19 Drugs
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 infection is the cause of the ongoing global pandemic. Mortality from COVID-19 infection is particularly high in patients with cardiovascular diseases. In addition, COVID-19 patients with preexisting cardiovascular comorbidities have a higher risk of death. Main cardiovascular complications of COVID-19 are myocardial infarction, myocarditis, acute myocardial injury, arrhythmias, heart failure, stroke, and venous thromboembolism. Therapeutic interventions in terms of drugs for COVID-19 have many cardiac adverse effects. Here, we review the relative the...
Source: Frontiers in Pharmacology - August 25, 2021 Category: Drugs & Pharmacology Source Type: research

Prognostic Genetic Markers for Thrombosis in COVID-19 Patients: A Focused Analysis on D-Dimer, Homocysteine and Thromboembolism
In this study, we aimed to uncover the genetic basis of the above conditions by examining genome-wide associations and tissue-specific gene expression to build a molecular network. Based on gene ontology, we annotated various SNPs with five ancestral terms: pulmonary embolism, venous thromboembolism, vascular diseases, cerebrovascular disorders, and stroke. The gene-gene interaction network revealed three clusters that each contained hallmark genes for D-dimer/fibrinogen levels, homocysteine levels, and arterial/venous thromboembolism with F2 and F5 acting as connecting nodes. We propose that genotyping COVID-19 patients f...
Source: Frontiers in Pharmacology - December 9, 2020 Category: Drugs & Pharmacology Source Type: research